Thanks for sharing! Some strong comments from the Chairman and CEO within this report:
"If the trial is successful we will need to be able to move quickly to commercialise our discoveries. To this end, the Board has undertaken a number of reviews to ensure that LCT has the expertise and experience necessary to take the company from a research-focused to a revenue-generating enterprise."
"We have also put in place plans to refocus the business should the outcome of the trial not be as successful as we might hope".
" As part of our preparations for the trial result we have developed a comprehensive marketing plan, identifying the best way to reach neurologists and potential patients and the information they will need to make an informed decision. We are working with a number of potential partners to put this plan in place".
"LCT has adopted a very conservative approach to the business of research and development. We prefer to make bold claims only when the evidence is in. Our top priority is always to ensure the science is world class".
LCT Price at posting:
23.5¢ Sentiment: Buy Disclosure: Held
